Kovack Advisors’s ImmunityBio IBRX Stock Holding History

Kovack Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189K	Sell	20,808 -1,400	-6%	-$10.6K	0.01%	1001
2026 Q1	$162K	Buy	22,208 +8,575	+63%	+$58.7K	0.01%	951
2025 Q4	$27K	Buy	+13,633	New	+$30.9K	﹤0.01%	1005

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kovack Advisors's IBRX Position: Q2 2026 in Review

Kovack Advisors reduced its ImmunityBio (IBRX) stake by 6.3% in Q2 2026, selling an estimated $10.6K and leaving 20,808 shares worth $189K. The position accounts for 0.01% of the portfolio, ranked #1001.

Kovack Advisors first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Kovack Advisors held 20,808 shares of ImmunityBio worth $189K as of Q2 2026.
Kovack Advisors sold 1,400 ImmunityBio shares in Q2 2026, an estimated $10.6K.
ImmunityBio made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #1001 holding.
Kovack Advisors first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.